Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund, page-47

Something would have to now go very wrong for it not to be the case:

"Paradigm remains on track for the protocol review by the US FDA to implement the 2mg/kg twice weekly dosing regimen into the next stage of the OA phase 3 program, anticipated in Q1 CY2024. Enrolment activities for next stage of the phase 3 OA clinical program are expected to commence in Q2 CY 2024."

Where do you get that from? Further follow-up studies have been completed.

Are you suggesting that's driven the staged dosage approach by FDA, whilst further studies completed?